womanofthehills
womanofthehills's JournalJoe Rogan would like to see Michelle Obama run -
'She's great, she's articulate, she's intelligent, she's the wife of the best President that we have had in our lifetime ... she can win,' Joe Rogan on possibility of Michelle Obama running in 2024
People on DU have mistakenly
posted that Joe is right wing but actually he is socially very progressive and was a Bernie supporter.
When South Park and NTF's are way over my head
https://twitter.com/bitfinexed/status/1474845683735793672?s=21Conflicting opinions in Israel over 4th dose - NYT
Dec. 23, 2021 by Isabel Kershner
JERUSALEM — Israel is considering whether to approve a fourth Covid-19 vaccine dose for vulnerable people to contain the fast-spreading Omicron variant, despite debate among scientists and a lack of evidence either for or against another booster.
The panel of experts advising the Israeli government on the pandemic recognized that uncertainty, but on Tuesday it recommended giving a fourth dose, concluding that the potential benefits outweighed the risks. It pointed to signs of waning immunity a few months after the third shot, and said that any delay in additional doses might prove too late to protect those most at risk.
But some scientists warned that the plan could backfire, because too many shots might cause a sort of immune system fatigue, compromising the body’s ability to fight the coronavirus. A few members of the government’s advisory panel raised that concern with respect to the elderly, according to a written summary of the discussion obtained by The New York Times.
Prime Minister Naftali Bennett, has made clear he supports a fourth shot, and Health Minister Nitzan Horowitz has suggested that a new round of boosters could get underway by Sunday. But by Thursday evening, the health ministry had not acted on the advice, and a senior ministry official said it was waiting for more data from other countries. Dec. 23, 2021 - I’m having trouble posting link - maybe because my subscription just ran out
United & Delta cancelling flights tomorrow (100 United, 90 Delta)
https://twitter.com/petemuntean/status/1474192146966237189?s=21Bernie urging Pres Biden to sack Louis DeJoy
Now, if you pay for priority mail - good luck for when it arrives. It used to be 2 - 3 days and now more like 5-6.
Bernie says medicines, Christmas presents not arriving on time and people who pay bills by mail are being charged late fees. This last one includes my cousin who I cannot convince to pay his bills online. Now, he’s pissed at the utilities when he should really be mad at the PO.
https://twitter.com/sensanders/status/1474017926546087937?s=21
More congresspeople need to do what AOC did -talk about accomplishments
https://twitter.com/aoc/status/1473693773196632072?s=21Good news - mild Covid long lasting antibodies- Washington Univ
People who have had a mild case of COVID-19 are left with long-term antibody protection against future disease, according to a study from researchers at Washington University School of Medicine in St. Louis.
https://medicine.wustl.edu/news/good-news-mild-covid-19-induces-lasting-antibody-protection/
German doctor gives thousands of homemade vaccines
https://twitter.com/forbes/status/1465813903854776325?s=21Moderna announces strategy
First, Moderna has already tested a higher dose booster of mRNA-1273 (100 µg) in healthy adults. Moderna has completed dosing of 306 participants in a safety and immunogenicity study of this high dose (100 µg) booster. The 100 µg dose of mRNA-1273 has also recently been studied by the National Institutes of Health (NIH) in the U.S. and has generally resulted in the highest neutralizing titers against prior SARS-CoV-2 strains. Moderna is working to rapidly test sera from its high dose booster recipients in neutralizing assays to determine if the 100 µg dose provides superior neutralizing protection against Omicron.
Second, Moderna is already studying two multi-valent booster candidates in the clinic that were designed to anticipate mutations such as those that have emerged in the Omicron variant. The first candidate (mRNA-1273.211) includes several mutations present in the Omicron variant that were also present in the Beta variant of concern1. The Company has completed dosing in a potentially pivotal safety and immunogenicity study of mRNA-1273.211 at the 50 µg (N=300) and 100 µg (N=584) dose levels. A second multi-valent candidate (mRNA-1273.213) includes many of the mutations present in the Omicron variant that were also present in the Beta and Delta variants2. The Company has completed dosing at the 100 µg (N=584) dose level and also plans to explore the 50 µg dose level in approximately 584 participants. Moderna will rapidly expand testing of sera from completed and ongoing multi-valent booster studies to determine if these multi-valent candidates are able to provide superior neutralizing protection against Omicron.
Third, Moderna will rapidly advance an Omicron-specific booster candidate (mRNA-1273.529). This candidate is part of the Company’s strategy to advance variant-specific candidates for a subset of variants of significant concern. During 2021 this has already included Beta- and Delta-specific boosters. The Company has repeatedly demonstrated the ability to advance new candidates to clinical testing in 60-90 days.
“From the beginning, we have said that as we seek to defeat the pandemic, it is imperative that we are proactive as the virus evolves. The mutations in the Omicron variant are concerning and for several days, we have been moving as fast as possible to execute our strategy to address this variant,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We have three lines of defense that we are advancing in parallel: we have already evaluated a higher dose booster of mRNA-1273 (100 µg), second, we are already studying two multi-valent booster candidates in the clinic that were designed to anticipate mutations such as those that have emerged in the Omicron variant and data is expected in the coming weeks, and third, we are rapidly advancing a Omicron-specific booster candidate (mRNA-1273.529
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-strategy-address-omicron-b11529-sars-cov-2/
Profile Information
Gender: FemaleHometown: New Mexico
Current location: New Mexico
Member since: Tue Apr 12, 2005, 11:15 PM
Number of posts: 8,690
